Personalis Inventory 2018-2024 | PSNL

Personalis inventory from 2018 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
Personalis Annual Inventory
(Millions of US $)
2024 $6
2023 $10
2022 $9
2021 $6
2020 $6
2019 $5
2018 $3
2017 $
Personalis Quarterly Inventory
(Millions of US $)
2024-12-31 $6
2024-09-30 $8
2024-06-30 $9
2024-03-31 $9
2023-12-31 $10
2023-09-30 $8
2023-06-30 $8
2023-03-31 $8
2022-12-31 $9
2022-09-30 $8
2022-06-30 $8
2022-03-31 $8
2021-12-31 $6
2021-09-30 $6
2021-06-30 $7
2021-03-31 $6
2020-12-31 $6
2020-09-30 $6
2020-06-30 $7
2020-03-31 $6
2019-12-31 $5
2019-09-30 $5
2019-06-30 $4
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.310B $0.085B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $17.427B 6.38
Dr Reddy's Laboratories (RDY) India $11.011B 21.00
BridgeBio Pharma (BBIO) United States $6.575B 0.00
Bausch Health Cos (BHC) Canada $2.381B 1.73
Supernus Pharmaceuticals (SUPN) United States $1.828B 17.06
Amphastar Pharmaceuticals (AMPH) United States $1.381B 8.33
Taysha Gene Therapies (TSHA) United States $0.285B 0.00
Assembly Biosciences (ASMB) United States $0.072B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00